M Blomback

Summary

Country: Sweden

Publications

  1. ncbi Scientific visits to the Aland Islands
    M Blomback
    Dept Laboratory Medicine Coagulation Research, Karolinska Institutet, Stockholm, Sweden
    Haemophilia 5:12-8. 1999
  2. ncbi Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study
    M Blomback
    Department of Laboratory Medicine Coagulation Research, Karolinska Institute Karolinska Hospital, Stockholm, Sweden
    Blood Coagul Fibrinolysis 9:1-9. 1998
  3. ncbi A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy
    M Blomback
    Department of Laboratory Medicine Coagulation Research, Karolinska Institute Karolinska Hospital, Stockholm, Sweden
    Blood Coagul Fibrinolysis 9:343-50. 1998
  4. ncbi The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX
    S He
    Coagulation Research, Department of Surgical Sciences, Unit of Clinical Allergy Research, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
    J Thromb Haemost 1:1215-9. 2003
  5. ncbi Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance
    A Antovic
    Coagulation Research Department of Surgical Sciences, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
    J Thromb Haemost 1:2531-5. 2003
  6. ncbi A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work
    S He
    Coagulation Research, Department of Surgical Sciences, L25, Karolinska Institutet, Karolinska Hospital, S 17176 Stockholm, Sweden
    Thromb Res 103:355-61. 2001
  7. doi Decreased fibrin network permeability and impaired fibrinolysis in the acute and convalescent phase of ischemic stroke
    E Rooth
    Department of Clinical Sciences, Division of Internal Medicine, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden
    Thromb Res 127:51-6. 2011
  8. ncbi Can the laboratory assay of protein C activity assist in monitoring the hemostatic function in pre-eclampsia?
    S He
    Department of Laboratory Medicine Coagulation Research, Karolinska Institute, Stockholm, Sweden
    Blood Coagul Fibrinolysis 10:127-32. 1999
  9. doi The plasma concentration of activated protein C appears normal in patients with haemophilia
    S Schulman
    Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
    Haemophilia 15:566-70. 2009
  10. ncbi Hypercoagulation in surgical postmenopausal women having hormone replacement with overdose estradiol
    S He
    Department of Surgical Sciences, Coagulation Research, Karolinska Institutet, Stockholm, Sweden
    Blood Coagul Fibrinolysis 12:677-81. 2001

Detail Information

Publications28

  1. ncbi Scientific visits to the Aland Islands
    M Blomback
    Dept Laboratory Medicine Coagulation Research, Karolinska Institutet, Stockholm, Sweden
    Haemophilia 5:12-8. 1999
    ..These mutations are probably due to a recombination between the vWF gene and its pseudogene, since both transitions are also present in the same location in the pseudogene...
  2. ncbi Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study
    M Blomback
    Department of Laboratory Medicine Coagulation Research, Karolinska Institute Karolinska Hospital, Stockholm, Sweden
    Blood Coagul Fibrinolysis 9:1-9. 1998
    ..Women weighing 50-79 kg at entry could be treated with 5000 IU of dalteparin once daily during pregnancy, without monitoring. Postpartum, many of the women were given a reduced dose...
  3. ncbi A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy
    M Blomback
    Department of Laboratory Medicine Coagulation Research, Karolinska Institute Karolinska Hospital, Stockholm, Sweden
    Blood Coagul Fibrinolysis 9:343-50. 1998
    ..The half-lives after a morning and an evening dose of 5000 IU dalteparin were 4.92 +/- 2.80 and 3.87 +/- 1.15 h, respectively (NS). There were no changes in thrombin marker levels during the two pharmacokinetic measurements...
  4. ncbi The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX
    S He
    Coagulation Research, Department of Surgical Sciences, Unit of Clinical Allergy Research, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
    J Thromb Haemost 1:1215-9. 2003
    ..The addition of rFVIIa to FVIII- or FIX-deficient systems altered the network structure, making the fibers thinner and more tightly packed...
  5. ncbi Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance
    A Antovic
    Coagulation Research Department of Surgical Sciences, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
    J Thromb Haemost 1:2531-5. 2003
    ..Activated thrombin generation and depressed fibrinolysis due to the presence of activated protein C (APC) resistance with or without factor (F)V Leiden mutation are associated with development of deep venous thrombosis (DVT)...
  6. ncbi A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work
    S He
    Coagulation Research, Department of Surgical Sciences, L25, Karolinska Institutet, Karolinska Hospital, S 17176 Stockholm, Sweden
    Thromb Res 103:355-61. 2001
    ..The above findings demonstrate that the modifications in the present study have rendered the method more effective for detecting haemostatic changes and relevant for monitoring treatments...
  7. doi Decreased fibrin network permeability and impaired fibrinolysis in the acute and convalescent phase of ischemic stroke
    E Rooth
    Department of Clinical Sciences, Division of Internal Medicine, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden
    Thromb Res 127:51-6. 2011
    ..We investigated fibrin network permeability and fibrinolysis in the acute and convalescent phase of ischemic stroke...
  8. ncbi Can the laboratory assay of protein C activity assist in monitoring the hemostatic function in pre-eclampsia?
    S He
    Department of Laboratory Medicine Coagulation Research, Karolinska Institute, Stockholm, Sweden
    Blood Coagul Fibrinolysis 10:127-32. 1999
    ..Thus, assays of protein C activity might not always assist in monitoring the hemostatic function during pre-eclamptic pregnancy...
  9. doi The plasma concentration of activated protein C appears normal in patients with haemophilia
    S Schulman
    Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
    Haemophilia 15:566-70. 2009
    ..Patients with haemophilia appear to generate normal concentrations of APC during basal conditions. APC does not seem to be an important modulator of the phenotypic expression of haemophilia...
  10. ncbi Hypercoagulation in surgical postmenopausal women having hormone replacement with overdose estradiol
    S He
    Department of Surgical Sciences, Coagulation Research, Karolinska Institutet, Stockholm, Sweden
    Blood Coagul Fibrinolysis 12:677-81. 2001
    ..Thus, the overdose estradiol replacement may not be beneficial in preventing CHD after menopause, or it may even increase the risk due to the hypercoagulable state induced therefrom...
  11. ncbi Accumulation of low molecular mass heparin during prophylactic treatment in pregnancy
    K Bremme
    Department of Woman and Child Health, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
    Blood Coagul Fibrinolysis 12:149-55. 2001
    ..The implications of an elevated anti-FXa activity during pregnancy, especially during the third trimester and at partus, are discussed. We present a reduced dose regime near term and during delivery...
  12. ncbi Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    J P Antovic
    Coagulation Research, Department of Surgical Sciences, Karolinska University Hospital, Stockholm, Sweden
    Scand J Clin Lab Invest 64:745-51. 2004
    ..The relationship between the TAFI activation pathway and bleeding complications associated with hemophilia A, hemophilia B and VWD requires further investigation...
  13. ncbi Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII
    J P Antovic
    Coagulation Research, Department of Surgical Sciences, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
    Haemophilia 8:781-6. 2002
    ..While this improvement slightly decreases, but still exists after 2 hours, it suggests efficacy in bleeding prevention using a protocol based on rFVIIa administration every 2 hours...
  14. ncbi Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A
    J Antovic
    Coagulation Research, Department of Surgical Sciences, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
    Haemophilia 7:557-60. 2001
    ..In this paper we use new nomenclature for TAFI, and we believe that this recommended terminology for different forms of TAFI can simplify further standardization in TAFI investigation...
  15. ncbi The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism
    A Antovic
    Coagulation Research Department of Surgical Sciences, Karolinska Institutet, Karolinska Hospital, Sweden
    Blood Coagul Fibrinolysis 13:181-6. 2002
    ..Additionally, analyses of thrombin generation markers are not useful to screen immediate changes in the haemostatic system after dalteparin injection...
  16. pmc Preanalytical conditions that affect coagulation testing, including hormonal status and therapy
    M Blomback
    Department of Molecular Medicine and Surgery, Coagulation Research, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 5:855-8. 2007
    ..While testing of these factors has not been exhaustive and some results are conflicting, guidelines for testing conditions can be given...
  17. ncbi Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor
    S He
    Coagulation Research Department in Surgical Sciences, Karolinska Institutet, S 17176, Stockholm, Sweden
    Thromb Res 103:241-8. 2001
    ..A high sensitivity of the mutated protein of VWF for the protease effect rather than increases in activity or quantity of the enzyme is probably involved in the pathogenesis of VWD 2A...
  18. ncbi Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion
    G J├Ârneskog
    Departments of Endocrinology and Diabetology, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden
    J Thromb Haemost 1:1195-201. 2003
    ..Patients with Type 1 diabetes have a tighter plasma fibrin gel structure, to which impaired glycemic control might contribute. Improved glycemic control can be achieved with continuous subcutaneous insulin infusion (CSII)...
  19. ncbi Measurement of blood and plasma coagulation time using free oscillating rheometry
    J S Ungerstedt
    Department of Surgical Sciences, Karolinska Institutet, Stockholm, Sweden
    Scand J Clin Lab Invest 62:135-40. 2002
    ..The technique and instrument used proved to be quick and easy to handle, and suitable for POCT as well as for examinations in the laboratory...
  20. ncbi Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C
    R Linder
    Department of Cardiology, Karolinska Hospital, Stockholm, Sweden
    Thromb Res 95:117-25. 1999
    ..This inhibition of the generation of activated protein C may also contribute to the rebound in cardiovascular events after withdrawal of effective antithrombotic treatment...
  21. doi Validation of a composite score for clinical severity of hemophilia
    S Schulman
    Coagulation Unit, Department of Hematology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 6:1113-21. 2008
    ..Evaluation of modulators of the phenotypic expression of hemophilia may benefit from a scoring system that reflects several aspects of the clinical severity instead of only one dimension...
  22. ncbi Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?
    J P Antovic
    Coagulation Research, Department of Surgical Sciences, Karolinska Hospital, Karolinska Insitute, Stockholm, Sweden
    Thromb Haemost 88:644-7. 2002
    ..It an be speculated that this mechanism can prevent more serious thrombotic complications in patients with PE and/or IUFGR...
  23. ncbi Modified clotting properties of fibrinogen in the presence of acetylsalicylic acid in a purified system
    S He
    Coagulation Research, Department of Surgical Sciences, Karolinska Institutet, Stockholm, Sweden
    Ann N Y Acad Sci 936:531-5. 2001
    ..It was concluded that ASA may directly or indirectly confer positive or negative effects on the stability of the fibrin clot and that the balance between these effects may be regulated by the ASA dose...
  24. ncbi Activation of the coagulation system occurs within rather than outside cutaneous haemangiomas
    J Antovic
    Department of Surgical Sciences, Karolinska Institutet, Stockholm, Sweden
    Acta Paediatr 90:1137-40. 2001
    ..Clinical signs of systemic disseminated intravascular coagulation were not observed...
  25. ncbi Evaluation of a new immunoturbidimetric test (Liatest antithrombin III) for determination of antithrombin antigen
    J Antovic
    Coagulation Research, Department of Surgical Sciences, Karolinska Institutet, Stockholm, Sweden
    Clin Lab Haematol 23:313-6. 2001
    ..It is suitable for measuring of AT antigen in routine laboratory work...
  26. pmc Nicotinamide is a potent inhibitor of proinflammatory cytokines
    J S Ungerstedt
    Coagulation Research, Department of Surgical Sciences, Karolinska Institutet, Stockholm, Sweden
    Clin Exp Immunol 131:48-52. 2003
    ..These findings demonstrate that nicotinamide has a potent immunomodulatory effect in vitro, and may have great potential for treatment of human inflammatory disease...
  27. ncbi Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time
    M Edlund
    Department of Women and Child Health, Karolinska Hospital, Stockholm, Sweden
    Blood Coagul Fibrinolysis 13:225-31. 2002
    ..The treatment was well tolerated and no serious adverse events were recorded. In conclusion, we find that nasal desmopressin is a possible complement for the medical treatment of menorrhagia...
  28. ncbi Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease
    P Bavenholm
    Department of Medicine, King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
    Thromb Haemost 73:568-75. 1995
    ..However, apolipoprotein B-containing lipoproteins appear to influence the relationships between insulin, insulin propeptides and haemostatic factors in individuals with premature coronary artery disease...